MarketPeel
Insider Trading Intelligence
BV

Bahram Valamehr

FATE
CHIEF R&D OFFICER · FATE THERAPEUTICS INC · CIK 0001748177
FILING MIX · LIFETIME30%/70%
BUYS
28
SELLS
66
TOTAL VALUE
$14.79M
COMPANIES
1
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
635,762
AVG SELL PX
$40.31
TRADE KIND
SHOWING 94 / 94
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
47 backtested trades · 8 horizons · 6 pending
Forward-return performance of every backtestable P/S trade by Bahram Valamehr, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d47+57.45%+3.27%+0.02%+3.25%+1.99%1.85
14d47+57.45%+2.21%+1.58%+0.63%-1.79%0.34
30d47+51.06%+5.07%+2.92%+2.15%-6.32%0.93
60d47+65.96%-5.49%+1.34%-6.83%-15.01%-2.28
90d47+82.98%-2.42%+1.25%-3.67%-18.57%-0.50
180d47(1 pending)+86.96%-10.95%+4.63%-15.58%-24.11%-2.05
1y47(2 pending)+88.89%-42.14%+8.21%-50.34%-75.20%-4.29
2y47(3 pending)+97.73%-78.10%+14.84%-92.94%-97.66%-19.89
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
FATE · 635,762 shares · as of May 20, 2026
0325,000650,000975,0001,300,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 28 buys / 66 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
FATE
FATE THERAPEUTICS INC
SALE
President and CEO
28,946$1.88$54.5K635,762May 20, 2026May 21, 2026View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
1,300,0001,300,000Jan 15, 2026Jan 16, 2026View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
335,000664,708Jan 15, 2026Jan 16, 2026View →
FATE
FATE THERAPEUTICS INC
SALE
President and CEO
5,190$1.07$5.6K329,708Jan 9, 2026Jan 12, 2026View →
FATE
FATE THERAPEUTICS INC
SALE
President and CEO
14,466$1.06$15.4K334,898Aug 4, 2025Aug 5, 2025View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
1,300,0001,300,000Jan 16, 2025Jan 16, 2025View →
FATE
FATE THERAPEUTICS INC
SALE
President and CEO
8,705$1.54$13.4K349,364Jan 10, 2025Jan 13, 2025View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
200,000358,069Jul 29, 2024Jul 31, 2024View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
450,000450,000Feb 1, 2024Feb 2, 2024View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
11,271$4.38$49.4K158,069Jan 9, 2024Jan 10, 2024View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
450,000450,000Feb 6, 2023Feb 7, 2023View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief R&D Officer
423$1.37$580169,340Jan 12, 2023Jan 13, 2023View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief R&D Officer
4230Jan 12, 2023Jan 13, 2023View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
10,917$5.24$57.2K168,917Jan 10, 2023Jan 11, 2023View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief R&D Officer
17,158$2.73$46.8K196,992Jul 7, 2022Jul 8, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
17,158$2.73$46.8K13,156Jul 7, 2022Jul 8, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
17,158$30.23$518.7K179,834Jul 7, 2022Jul 8, 2022View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief R&D Officer
5,842$2.73$15.9K187,676Jul 6, 2022Jul 7, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
2,000$4.84$9.7K8,704Jul 6, 2022Jul 7, 2022View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief R&D Officer
2,000$4.84$9.7K181,834Jul 6, 2022Jul 7, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
7,842$30.07$235.8K179,834Jul 6, 2022Jul 7, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
5,842$2.73$15.9K30,314Jul 6, 2022Jul 7, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
100$34.04$3.4K179,834Mar 14, 2022Mar 15, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
2,960$33.30$98.6K179,934Mar 14, 2022Mar 15, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
3,067$31.66$97.1K185,089Mar 14, 2022Mar 15, 2022View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief R&D Officer
25,000$2.73$68.3K204,834Mar 14, 2022Mar 15, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
16,678$30.36$506.3K188,156Mar 14, 2022Mar 15, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
25,00036,156Mar 14, 2022Mar 15, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
2,195$32.49$71.3K182,894Mar 14, 2022Mar 15, 2022View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
53,05853,058Jan 25, 2022Jan 27, 2022View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
33,302179,834Jan 25, 2022Jan 27, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
4,152$48.44$201.1K146,950Jan 11, 2022Jan 13, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
418$49.12$20.5K146,532Jan 11, 2022Jan 13, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
351$47.17$16.6K151,102Jan 10, 2022Jan 12, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
5,245$46.33$243.0K151,453Jan 10, 2022Jan 12, 2022View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
6,564$47.61$312.5K166,016Dec 13, 2021Dec 14, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
7,018$46.72$327.9K172,580Dec 13, 2021Dec 14, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
2,100$45.68$95.9K179,598Dec 13, 2021Dec 14, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
1,600$49.27$78.8K156,698Dec 13, 2021Dec 14, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief R&D Officer
25,000$2.73$68.3K181,698Dec 13, 2021Dec 14, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief R&D Officer
25,00061,156Dec 13, 2021Dec 14, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief R&D Officer
7,718$48.75$376.3K158,298Dec 13, 2021Dec 14, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
60,958156,698Nov 19, 2021Nov 22, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
15,809$65.94$1.04M104,931Sep 13, 2021Sep 14, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief Development Officer
25,000$2.73$68.3K120,740Sep 13, 2021Sep 14, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
800$67.46$54.0K95,740Sep 13, 2021Sep 14, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
8,391$66.84$560.9K96,540Sep 13, 2021Sep 14, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
25,00086,156Sep 13, 2021Sep 14, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief Development Officer
16,156$2.90$46.9K111,896Jun 14, 2021Jun 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
16,380$89.11$1.46M104,360Jun 14, 2021Jun 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
16,1560Jun 14, 2021Jun 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
400$90.76$36.3K95,740Jun 14, 2021Jun 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
8,220$89.68$737.2K96,140Jun 14, 2021Jun 16, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief Development Officer
8,844$2.73$24.1K120,740Jun 14, 2021Jun 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
8,844111,156Jun 14, 2021Jun 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
8,416$91.94$773.8K108,367Mar 15, 2021Mar 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
3,957$90.89$359.7K116,783Mar 15, 2021Mar 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
8,404$92.64$778.6K99,963Mar 15, 2021Mar 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
25,00016,156Mar 15, 2021Mar 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
25,000$2.90$72.5K120,740Mar 15, 2021Mar 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
1,018$94.59$96.3K95,740Mar 15, 2021Mar 16, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
3,205$93.75$300.5K96,758Mar 15, 2021Mar 16, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
18,01395,740Jan 20, 2021Jan 22, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
6,8516,851Jan 20, 2021Jan 22, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
1,332$111.62$148.7K79,649Jan 11, 2021Jan 12, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
871$109.65$95.5K77,727Jan 11, 2021Jan 12, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
1,051$110.76$116.4K78,598Jan 11, 2021Jan 12, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
2,451$117.15$287.1K82,004Jan 8, 2021Jan 12, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
151$114.76$17.3K80,981Jan 8, 2021Jan 12, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
872$115.80$101.0K81,132Jan 8, 2021Jan 12, 2021View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
2,756$117.60$324.1K84,455Jan 8, 2021Jan 12, 2021View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief Development Officer
25,000$2.90$72.5K112,211Dec 14, 2020Dec 15, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
2,946$97.70$287.8K95,687Dec 14, 2020Dec 15, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
400$100.97$40.4K88,317Dec 14, 2020Dec 15, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
1,813$95.89$173.9K110,398Dec 14, 2020Dec 15, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
11,765$96.65$1.14M98,633Dec 14, 2020Dec 15, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
3,148$98.80$311.0K92,539Dec 14, 2020Dec 15, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
100$102.75$10.3K87,211Dec 14, 2020Dec 15, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
3,822$99.77$381.3K88,717Dec 14, 2020Dec 15, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
25,00041,156Dec 14, 2020Dec 15, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
1,006$102.06$102.7K87,311Dec 14, 2020Dec 15, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
3,0760Sep 14, 2020Sep 16, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
16,784$36.03$604.7K94,827Sep 14, 2020Sep 16, 2020View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief Development Officer
21,924$2.90$63.6K112,211Sep 14, 2020Sep 16, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
600$37.49$22.5K87,211Sep 14, 2020Sep 16, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
21,92466,156Sep 14, 2020Sep 16, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
7,016$36.93$259.1K87,811Sep 14, 2020Sep 16, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
600$34.65$20.8K111,611Sep 14, 2020Sep 16, 2020View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief Development Officer
3,076$1.69$5.2K90,287Sep 14, 2020Sep 16, 2020View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief Development Officer
1,153$1.69$1.9K87,211Feb 3, 2020Feb 4, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
1,1530Feb 3, 2020Feb 4, 2020View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Development Officer
5,700$20.69$117.9K86,058Jan 8, 2020Jan 10, 2020View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
90,00090,000Jan 8, 2020Jan 10, 2020View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
25,00091,758Jan 8, 2020Jan 10, 2020View →
Other insiders · FATE
Loading peer insiders…
About this filer
CIK 0001748177
ROLE
Chief R&D Officer
PRIMARY
FATE
COMPANIES
1
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001748177DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback